These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The role of Fas ligand as an effector molecule in corneal graft rejection. Stuart PM; Yin X; Plambeck S; Pan F; Ferguson TA Eur J Immunol; 2005 Sep; 35(9):2591-7. PubMed ID: 16114107 [TBL] [Abstract][Full Text] [Related]
4. Protection of islet allografts transplanted together with Fas ligand expressing testicular allografts. Takeda Y; Gotoh M; Dono K; Nishihara M; Grochowiecki T; Kimura F; Yoshida T; Ohta Y; Ota H; Ohzato H; Umeshita K; Takeda T; Matsuura N; Sakon M; Kayagaki N; Yagita H; Okumura K; Miyasaka M; Monden M Diabetologia; 1998 Mar; 41(3):315-21. PubMed ID: 9541172 [TBL] [Abstract][Full Text] [Related]
5. Evidence that retinal pigment epithelium functions as an immune-privileged tissue. Wenkel H; Streilein JW Invest Ophthalmol Vis Sci; 2000 Oct; 41(11):3467-73. PubMed ID: 11006240 [TBL] [Abstract][Full Text] [Related]
7. IL-5 mediates eosinophilic rejection of MHC class II-disparate skin allografts in mice. Le Moine A; Surquin M; Demoor FX; Noël JC; Nahori MA; Pretolani M; Flamand V; Braun MY; Goldman M; Abramowicz D J Immunol; 1999 Oct; 163(7):3778-84. PubMed ID: 10490975 [TBL] [Abstract][Full Text] [Related]
8. Induction of antitumor immunity with Fas/APO-1 ligand (CD95L)-transfected neuroblastoma neuro-2a cells. Shimizu M; Fontana A; Takeda Y; Yagita H; Yoshimoto T; Matsuzawa A J Immunol; 1999 Jun; 162(12):7350-7. PubMed ID: 10358186 [TBL] [Abstract][Full Text] [Related]
9. CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival. Stuart PM; Griffith TS; Usui N; Pepose J; Yu X; Ferguson TA J Clin Invest; 1997 Feb; 99(3):396-402. PubMed ID: 9022072 [TBL] [Abstract][Full Text] [Related]
10. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways. Zimmerman Z; Shatry A; Deyev V; Podack E; Mammolenti M; Blazar BR; Yagita H; Levy RB Biol Blood Marrow Transplant; 2005 Aug; 11(8):576-86. PubMed ID: 16041307 [TBL] [Abstract][Full Text] [Related]
11. Perforin- and Fas-mediated cytotoxic pathways are not required for allogeneic resistance to bone marrow grafts in mice. Baker MB; Podack ER; Levy RB Biol Blood Marrow Transplant; 1995 Dec; 1(2):69-73. PubMed ID: 9118294 [TBL] [Abstract][Full Text] [Related]
12. Immune privilege and immunogenicity reside among different layers of the mouse cornea. Hori J; Joyce NC; Streilein JW Invest Ophthalmol Vis Sci; 2000 Sep; 41(10):3032-42. PubMed ID: 10967061 [TBL] [Abstract][Full Text] [Related]
13. Induction of specific T cell tolerance by Fas ligand-expressing antigen-presenting cells. Zhang HG; Su X; Liu D; Liu W; Yang P; Wang Z; Edwards CK; Bluethmann H; Mountz JD; Zhou T J Immunol; 1999 Feb; 162(3):1423-30. PubMed ID: 9973398 [TBL] [Abstract][Full Text] [Related]
14. Critical role of Fas/Fas ligand interaction in CD28-independent pathway of allogeneic murine hepatocyte rejection. Kawahara T; Kasai S; Yagita H; Sawa M; Kato K; Azuma M; Nakajima A; Okumura K; Futagawa S; Mito M Hepatology; 1997 Oct; 26(4):944-8. PubMed ID: 9328317 [TBL] [Abstract][Full Text] [Related]
15. Limitations of CD95 ligand-transduced killer dendritic cells to prevent graft rejections. Kusuhara M; Matsue H Exp Dermatol; 2005 Apr; 14(4):273-80. PubMed ID: 15810885 [TBL] [Abstract][Full Text] [Related]
16. Deregulated c-Myc prematurely recruits both Type I and II CD95/Fas apoptotic pathways associated with terminal myeloid differentiation. Amanullah A; Liebermann DA; Hoffman B Oncogene; 2002 Feb; 21(10):1600-10. PubMed ID: 11896589 [TBL] [Abstract][Full Text] [Related]
17. Dendritic cells are resistant to apoptosis through the Fas (CD95/APO-1) pathway. Ashany D; Savir A; Bhardwaj N; Elkon KB J Immunol; 1999 Nov; 163(10):5303-11. PubMed ID: 10553053 [TBL] [Abstract][Full Text] [Related]
18. Differential involvement of the CD95 (Fas/APO-1) receptor/ligand system on apoptosis induced by the wild-type p53 gene transfer in human cancer cells. Fukazawa T; Fujiwara T; Morimoto Y; Shao J; Nishizaki M; Kadowaki Y; Hizuta A; Owen-Schaub LB; Roth JA; Tanaka N Oncogene; 1999 Apr; 18(13):2189-99. PubMed ID: 10327065 [TBL] [Abstract][Full Text] [Related]
19. Fas/Fas ligand signaling during gestational T cell development. Fleck M; Zhou T; Tatsuta T; Yang P; Wang Z; Mountz JD J Immunol; 1998 Apr; 160(8):3766-75. PubMed ID: 9558079 [TBL] [Abstract][Full Text] [Related]
20. Overexpression of Fas ligand does not confer immune privilege to a pancreatic beta tumor cell line (betaTC-3). Okamoto S; Takamizawa S; Bishop W; Wen J; Kimura K; Sandler A J Surg Res; 1999 Jun; 84(1):77-81. PubMed ID: 10334893 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]